Trending Now

Important medical research and remarkable case reports worth knowing.

Selected from high-relevance medical literature published in the last 14 days.

FeaturedClinical ResearchUrology

Diagnostic yield and early outcomes of radical prostatectomy without prior histopathologic diagnosis: a single-arm systematic review and meta-analysis.

World J UrolNov 10, 2026Open access

This single-arm systematic review and random-effects meta-analysis assessed radical prostatectomy without prior histopathologic confirmation in adult men with high clinical suspicion of clinically significant prostate…

Why it matters

The findings suggest that imaging and clinical risk assessment can identify a group in whom prostatectomy without prior biopsy often yields clinically significant cancer, with few benign surgical specimens.

Read summary

Also worth knowing

Clinical ResearchOncology (Medical)

Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial.

This prospective, single-arm phase II trial evaluated sequential anlotinib and radioiodine (RAI) in patients with measurable distant metastatic differentiated thyroid cancer (DTC).

OncologistNov 5, 2026Read summary
Clinical ResearchNuclear Medicine

Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas.

This phase I, first-in-human study evaluated the safety, biodistribution, dosimetry, and preliminary efficacy of the dual-targeting radioligand 177Lu-LNC1009 in nine patients with advanced solid tumors and positive…

J Nucl MedNov 2, 2026Read summary
Clinical ResearchOncology (Medical)Open access

Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.

This prospective clinical trial assessed a personalized sequence of intraarterial then intravenous 177Lu-DOTATATE in 10 adults with progressive, nonresectable, liver-dominant metastatic gastroenteropancreatic…

J Nucl MedNov 2, 2026Read summary
Clinical ResearchNuclear Medicine

Phase 2 Trial of 89 Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.

This prospective phase 2 trial compared CD38-targeted 89Zr-DFO-daratumumab immuno-PET/CT with standard-of-care 18F-FDG PET/CT in 60 participants with multiple myeloma.

RadiologyNov 1, 2026Read summary
Looking for an earlier article?Everything that has appeared in Trending is in the archive.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.